证券代码：603718 证券简称：海利生物 公告编号：2024-025 上海海利生物技术股份有限公司 关于筹划重大资产重组暨签署《股权收购意向协议书》 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 1、上海海利生物技术股份有限公司（以下简称"公司"）正在筹划以支付现金 的方式向美伦管理有限公司购买其持有的陕西瑞盛生物科技有限公司（以下简称"瑞 盛生物"、"标的公司"或"目标公司"）55%股权（以下简称"本次交易"）。本 次交易完成后，瑞盛生物将成为公司的控股子公司。 2024 年 6 月 11 日公司召开第五届董事会第二次会议，会议审议通过了《关于筹 划重大资产重组暨签署<股权收购意向协议书>的议案》，并于 2024 年 6 月 11 日与交 易相关方签订《股权收购意向协议书》（以下简称"意向协议书"）。本次交易的预 估值为 8.8 至 9.6 亿元人民币，本次签署的协议仅为意向性协议，最终交易价格尚需 在完成审计、评估后，由交易各方进一步协商确定，并以各方签署的正式协议为准。 2、根据初 ...

证券代码：603718 证券简称：海利生物 公告编号：2024－024 上海海利生物技术股份有限公司 第五届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 具体详见公司于同日在证券时报、证券日报及上海证券交易所网站 （www.sse.com.cn）披露的《海利生物关于向银行申请授信额度的公告》。 表决结果：7 票同意、0 票反对、0 票弃权。 三、备查文件 1、第五届董事会第二次会议决议； 上海海利生物技术股份有限公司（以下简称"公司"）第五届董事会第二次 会议（以下简称"本次会议"）于 2024 年 6 月 11 日以现场表决方式召开。本次 董事会会议应参加董事 7 人，实际参加董事 7 名。经全体董事同意，本次会议豁 免通知时限要求。本次会议符合《中华人民共和国公司法》、《上海海利生物技 术股份有限公司章程》（以下简称"《公司章程》"）和《上海海利生物技术股 份有限公司董事会议事规则》的有关规定，会议的召集、召开、表决合法有效。 二、董事会会议审议情况 经审议，本次董 ...

证券代码：603718 证券简称：海利生物 公告编号：2024-018 上海海利生物技术股份有限公司 关于 2023 年年度股东大会取消部分议案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 股东大会有关情况 1、 股东大会的类型和届次 2023 年年度股东大会 2、 股东大会召开日期： 2024 年 5 月 23 日 3、 股东大会股权登记日： | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | Ａ股 | 603718 | 海利生物 | 2024/5/17 | 二、 取消议案的情况说明 1、 取消议案名称 | 序号 | 议案名称 | | --- | --- | | 8 | 关于续聘会计师事务所的议案 | 2、 取消议案原因 公司于 2024 年 5 月 16 日召开第四届董事会第二十二次会议和第四届监事 会第十八次会议，审议通过了《关于 2023 年年度股东大会取消部分议案的议案》。 鉴于公司拟聘任的会计师事务所大华会计师事务所（特殊普通合伙）被 ...

上海海利生物技术股份有限公司 2023 年年度股东大会会议资料 二〇二四年五月 上海 上海海利生物技术股份有限公司 2023 年年度股东大会议程 一、现场会议召开时间 2024 年 5 月 23 日（星期四）13:30 二、网络投票时间 1、互联网投票平台投票时间：2024 年 5 月 23 日的 9:15－15:00 2、交易系统投票平台投票时间：2024 年 5 月 23 日的交易时间段，即 9:15 －9:25，9:30－11:30，13:00－15:00 三、现场会议召开地点 上海市长宁区江苏路 369 号 11 楼会议室 三、会议主持 董事长张海明先生 四、会议议程 （一）董事长宣布 2023 年年度股东大会开始，报告出席会议的股东人数及 代表股份总数 （二）介绍出席会议的董事、监事、高级管理人员、见证律师等人员情况 （三）宣读和审议会议议案 非累积投票议案： 1、2023 年度董事会工作报告 1 2、2023 年年度报告全文及摘要 3、2023 年度财务决算报告及 2024 年度财务预算报告 4、2023 年度内部控制评价报告 5、关于 2023 年度利润分配方案的议案 6、2023 年度独立董事 ...

证券代码：603718 证券简称：海利生物 公告编号：2024－017 上海海利生物技术股份有限公司 第四届监事会第十八次会议决议公告 一、监事会会议召开情况 上海海利生物技术股份有限公司（以下简称"公司"）第四届监事会第十八 次会议（以下简称"本次会议"）于 2024 年 5 月 16 日以通讯表决方式召开。经 全体监事同意，本次会议豁免通知时限要求。本次监事会会议应参加监事 3 人， 实际参加监事 3 名。本次会议符合《中华人民共和国公司法》、《上海海利生物技 术股份有限公司章程》（以下简称"《公司章程》"）和《上海海利生物技术股份有 限公司监事会议事规则》的有关规定，会议的召集、召开、表决合法有效。经全 体监事审议和表决，形成了以下决议。 二、监事会会议审议情况 1、审议通过了《关于 2023 年年度股东大会取消部分议案的议案》 鉴于公司拟聘任的会计师事务所大华会计师事务所（特殊普通合伙）被暂停 从事证券服务业务 6 个月，经与其协商，基于谨慎性原则，公司决定取消 2023 年年度股东大会中第 8 项提案，即《关于续聘会计师事务所的议案》。公司聘请 2024 年度审计机构事项将另行召开董事会并提交股东大 ...

证券代码：603718 证券简称：海利生物 公告编号：2024－016 1、第四届董事会第二十二次会议决议； 2、第四届董事会审计委员会 2024 年度第一次会议决议。 上海海利生物技术股份有限公司 第四届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、董事会会议审议情况 1、审议通过了《关于 2023 年年度股东大会取消部分议案的议案》 鉴于公司拟聘任的会计师事务所大华会计师事务所（特殊普通合伙）被暂停 从事证券服务业务 6 个月，经与其协商，基于谨慎性原则，公司决定取消 2023 年年度股东大会中第 8 项提案，即《关于续聘会计师事务所的议案》。公司聘请 2024 年度审计机构事项将另行召开董事会并提交股东大会审议。 已经公司第四届董事会审计委员会 2024 年度第一次会议审议通过。具体内 容详见公司同日在上海证券交易所披露的《上海海利生物技术股份有限公司关于 2023 年年度股东大会取消部分议案的公告》。 表决结果：7 票同意、0 票反对、0 票弃权。 三、备查文件 一、董事会会议 ...

Financial Performance - The company achieved a net profit attributable to the parent company of RMB 62,870,202.71 for the fiscal year 2023, with distributable profits for shareholders amounting to RMB 426,801,334.54[6]. - In 2023, the company's operating revenue decreased by 19.76% to CNY 240,722,981.59 compared to CNY 299,991,674.85 in 2022[21]. - The net profit attributable to shareholders fell by 48.30% to CNY 62,870,202.71 from CNY 121,607,849.73 in the previous year[21]. - The net cash flow from operating activities dropped significantly by 102.86%, resulting in a negative cash flow of CNY -8,367,280.38[21]. - The basic earnings per share decreased by 47.37% to CNY 0.10, down from CNY 0.19 in 2022[22]. - The company's total assets increased by 9.48% to CNY 1,657,749,783.34 compared to CNY 1,514,252,528.46 at the end of 2022[21]. - The weighted average return on equity decreased by 6.01 percentage points to 5.32% from 11.33% in the previous year[22]. - The gross profit margin for the main business was 50.24%, down 8.70% year-on-year[53]. - Revenue from veterinary biological products was CNY 123.30 million, a decline of 35.61% year-on-year[53]. - The gross margin for veterinary biological products was 39.73%, down by 13.77% year-on-year[78]. Profit Distribution - A cash dividend of RMB 0.287 per 10 shares (including tax) is proposed for the profit distribution plan for the fiscal year 2023[6]. - The cash dividend ratio for the year is 30.03%, which represents the total cash dividend amount as a percentage of the net profit attributable to shareholders[155]. - The company will distribute at least 30% of the distributable profits as cash dividends if there are no major investment plans or significant cash expenditures[149]. - The board of directors will propose the profit distribution plan annually based on the company's profitability and cash flow situation, which will then be submitted for shareholder approval[150]. - The company has confirmed that the cash dividend policy complies with its articles of association and shareholder resolutions[153]. Risk Management and Compliance - The company emphasizes the importance of risk management and has detailed various operational risks and corresponding mitigation strategies in the report[7]. - The report outlines the company's commitment to compliance with regulatory standards and practices in its operations[7]. - The company has not faced any violations in decision-making procedures regarding external guarantees[7]. - The company confirms that there are no non-operational fund occupations by controlling shareholders or related parties[7]. - The company is committed to enhancing internal management and compliance to mitigate operational risks and improve corporate governance[104]. Corporate Governance - The board of directors and supervisory board members have all attended the board meeting, ensuring governance transparency[6]. - The company has established a modern corporate governance structure, ensuring equal rights for all shareholders, particularly minority shareholders[112]. - The board of directors and supervisory board comply with legal requirements and actively participate in training to fulfill their responsibilities[113]. - The company has implemented a strict information disclosure management system to ensure timely and accurate communication with shareholders[114]. - The company has revised its internal control systems and governance documents to comply with new regulations regarding independent directors[115]. Research and Development - The company has increased its R&D investment and established a research center in collaboration with Northwest A&F University, enhancing its innovation capabilities[32]. - The company aims to launch at least five new products annually, ensuring continuous innovation and development[46]. - The company has invested in expanding its R&D facilities by over 1,300 square meters to enhance the development of key raw materials[79]. - The company is focusing on R&D strategies that combine market orientation with technological upgrades to enhance product offerings[79]. - The company’s R&D investment in recombinant antibodies was 690.84 million RMB, showing an increase of 80.64% compared to the previous year[85]. Market and Business Strategy - The company has restructured its business focus towards the more profitable "human health" sector, particularly through its subsidiary, Shanghai Jiemen Biotechnology Co., which specializes in IVD products[39]. - The company aims to strengthen its competitive position in the market by focusing on high-quality products and innovative R&D capabilities[36]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the I sector[199]. - The company is actively seeking domestic suppliers to reduce import dependency and is increasing investment in raw material R&D to diversify product offerings[110]. - The company plans to implement a "full staff marketing" strategy in 2024, ensuring existing government procurement markets are maintained while expanding into new regions and reducing service fees[102]. Environmental and Social Responsibility - The company invested 18.19 million yuan in environmental protection during the reporting period[168]. - The company has established an environmental management system in accordance with GB/T24001—2004/ISO14001:2004, with no environmental pollution incidents reported in 2023[183]. - The company actively participated in social responsibility initiatives, including donating RMB 37,500 worth of disaster relief materials during the 2023 flood in Baoding, Hebei[187]. - The company has been recognized as a "Demonstration Point for Party Branch Construction" by the district committee, enhancing its operational capabilities[182]. - The company is committed to maintaining a harmonious relationship with society, the environment, and its stakeholders[186]. Employee Management - The total number of employees at the parent company and major subsidiaries is 295, with 125 in production, 39 in sales, and 86 in technical roles[142]. - The company emphasizes a broad salary policy based on job value and individual capability, implementing performance assessments to motivate employees[144]. - The company organized various training programs for management and staff, enhancing quality awareness and professional skills[145]. - The company has a comprehensive employee welfare system and actively conducts various training and team-building activities[178]. - The employee stock ownership plan is designed to align employee interests with company performance, enhancing retention and motivation[200].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 70,304,397.74, a decrease of 1.31% compared to the same period last year[3]. - The net profit attributable to shareholders was CNY -3,719,366.81, representing a decline of 126.13% year-over-year[3]. - Basic earnings per share were CNY -0.01, a decrease of 126.13% year-over-year[3]. - The company's gross profit margin decreased, with a gross profit of ¥30,750,596.80 in Q1 2024, down from ¥42,936,674.43 in Q1 2023[21]. - Net profit for Q1 2024 was a loss of ¥4,361,103.22, compared to a profit of ¥13,593,233.44 in Q1 2023[21]. - The company reported a comprehensive loss of ¥12,631,759.31 for Q1 2024, compared to a comprehensive income of ¥16,633,993.44 in Q1 2023[22]. Cash Flow - The net cash flow from operating activities was CNY -1,229,734.74, down 96.54% compared to the previous year[3]. - Cash flow from operating activities was ¥51,603,053.97, down from ¥62,861,217.44 in Q1 2023, indicating a decline in cash generation[24]. - The net cash flow from operating activities was -$1,229,734.74, a significant decrease from -$35,585,211.73 in the previous quarter[25]. - Total cash inflow from investment activities was $151,043,125.22, compared to $261,854,894.77 in the previous quarter, indicating a decline of approximately 42.4%[25]. - The net cash flow from investment activities was -$68,810,882.78, worsening from -$42,177,186.39 in the previous quarter[25]. - Cash inflow from financing activities totaled $20,000,000.00, while cash outflow was $30,434,991.67, resulting in a net cash flow of -$10,434,991.67[26]. - The ending cash and cash equivalents balance was $56,618,265.57, down from $78,666,223.80 in the previous quarter[26]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,645,165,559.81, a decrease of 0.76% from the end of the previous year[4]. - The company's cash and cash equivalents decreased to CNY 60,261,265.57 from CNY 140,736,190.61 at the end of 2023[16]. - The total liabilities decreased to ¥464,460,489.17 from ¥482,957,571.38 year-over-year[21]. - The company reported a total current liability of CNY 282,667,886.09, down from CNY 300,505,988.19 at the end of 2023[17]. Shareholder Information - The equity attributable to shareholders increased by 0.54% to CNY 1,223,533,561.83 compared to the end of the previous year[4]. - The total number of ordinary shareholders at the end of the reporting period was 34,263[8]. - The top ten shareholders held a total of 226,197,938 shares, accounting for 34.38% of the total shares[8]. - The total equity attributable to shareholders increased slightly to ¥1,223,533,561.83 from ¥1,216,978,966.74 in the previous year[21]. Expenses - The company recognized stock incentive expenses of CNY 14,295,625.00, which reduced net profit by CNY 11,518,012.50[4]. - The company recognized equity incentive expenses of CNY 14,295,625, resulting in a net profit reduction of CNY 11,518,012.50; excluding this impact, the net profit attributable to shareholders would be CNY 7,798,645.69[12]. - Total operating costs increased significantly to ¥79,483,781.34, up 30% from ¥61,195,825.19 in the same period last year[21]. - Research and development expenses were ¥5,495,990.24, a decrease of 16.8% from ¥6,604,724.12 in Q1 2023[21]. Other Financial Metrics - The weighted average return on equity was 0.30%, a decrease of 1.54 percentage points year-over-year[3]. - Accounts receivable rose to CNY 96,564,957.56 from CNY 84,947,031.64 at the end of 2023[16]. - Inventory decreased to CNY 93,045,354.79 from CNY 102,823,736.71 at the end of 2023[16]. - Short-term borrowings increased to CNY 70,000,000.00 from CNY 50,000,000.00 at the end of 2023[17]. - The impact of exchange rate changes on cash and cash equivalents was $684.15, contrasting with -$3,078.84 in the previous quarter[26].

证券代码：603718 证券简称：海利生物 公告编号：2024-014 上海海利生物技术股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海海利生物技术股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发布公司 2023 年度报告，为便于广大投资者更全面深入地了解公司 2023 年 度经营成果、财务状况，公司计划于 2024 年 05 月 15 日 下午 13:00-14:00 举 行 2023 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 05 月 15 日 下午 13:00-14:00 会议召开时间：2024 年 05 月 15 日(星期三) 下午 13:00-14:00 会议召开地点：上海 ...

根据中国证监会上海监管局《关于对张悦采取出具警示函措施 的决定》（沪证监决〔2023〕376 号，以下简称《警示函》）查明的事 实及相关公告，上海海利生物技术股份有限公司（以下简称公司） 在 2021 年半年报中，披露财务费用少计关联方借款利息 327.40 万 元，占当期报告记载利润总额的 11.40%。2021 年三季报中，公司披 露财务费用少计关联方借款利息 635.05 万元，占当期报告记载利润 总额的 14.74%。2022 年一季报中，公司披露财务费用少计关联方借 款利息 295.50 万元，占当期报告记载利润总额的 22.70%。 定期报告是投资者关注的事项，可能对公司股价及投资者决策 产生影响，公司理应根据会计准则对当期财务数据进行客观、谨慎 地核算并披露。公司披露的财务数据披露不准确，上述行为违反了 《公开发行证券的公司信息披露编报规则第 15 号——财务报告的一 般规定》以及《上海证券交易所股票上市规则（2022 年修订）》（以 下简称《股票上市规则》）第 1.4 条、第 2.1.1 条、第 2.1.4 条等有 1 上 海 证 券 交 易 所 上证公监函〔2024〕0094 号 关于对上海 ...